Monday , September 25 2017
Home / 2016 / January

Monthly Archives: January 2016

InterSystems and Pulse Infoframe Partner for Patient Registry Solutions

CAMBRIDGE, Mass. & LONDON, Ontario–(BUSINESS WIRE)–InterSystems, a global leader in healthcare information technology, has partnered with Pulse Infoframe, leader in collaborative research and patient registry solutions, to facilitate clinical research and population health studies. Leveraging the InterSystems HealthShare® health informatics platform for interoperability between clinical research systems and electronic health …

Read More »

MD Anderson Joins US Cancer Centers Endorsing HPV Vaccination for Prevention

In response to low national vaccination rates for the human papillomavirus (HPV), The University of Texas MD Anderson Cancer Center has joined with the 68 other National Cancer Institute (NCI)-designated cancer centers in issuing a statement calling for increased HPV vaccination for the prevention of cancer. These institutions collectively recognize …

Read More »

Illumina Acquires Conexio Genomics

Building on Illumina’s work to develop next-generation sequencing (NGS) solutions for the HLA typing market, Illumina recently announced its acquisition of Conexio Genomics, a world leader in the development of HLA typing solutions. “The addition of Conexio products and people solidify our HLA capabilities and demonstrate Illumina’s ongoing commitment to …

Read More »

Cost and Value

Where does the true value of cancer treatment lie? Oncology experts grapple with this important question, with one of the more recent people to chime in being Robert C. Young, M.D., of RCY Medicine in Philadelphia, in an essay in a recent issue of the New England Journal of Medicine. Dr. …

Read More »

Geisinger Researchers Discover 17 Genes Related to Brain Disorders

DANVILLE, Pa., Jan. 27, 2016 /PRNewswire-USNewswire/ — A recent study led by a team of researchers at Geisinger Health System’s Autism & Developmental Medicine Institute (ADMI) identified 17 new genes causing autism and other related brain disorders, including intellectual disability/developmental delay, epilepsy, attention deficit hyperactivity disorder, schizophrenia, and bipolar disorder. …

Read More »

FDA Accepts Amgen’s BLA for its Humira Biosimilar

THOUSAND OAKS, Calif., Jan. 25, 2016 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Amgen’s Biologics License Application (BLA) for ABP 501, a biosimilar candidate to Humira® (adalimumab). “If approved, we believe ABP 501 could serve as an important additional approved …

Read More »

FDA Accepts Merck’s BLA for Bezlotoxumab in C. difficile Prevention

KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for bezlotoxumab, an investigational antitoxin for prevention of Clostridium difficile (C. difficile) infection recurrence. The FDA granted Priority …

Read More »

Lilly and Roche Diagnostics Partner on Alzheimer’s Disease Adjunct Diagnostic Tool

INDIANAPOLIS, Jan. 27, 2016 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced an arrangement to partner with Roche Diagnostics on its ongoing development of a commercially scalable cerebrospinal fluid assay for amyloid-beta 1-42. Together with tau tangles, the presence of amyloid in the brain is a key marker …

Read More »

Alkermes Initiates Clinical Testing of its Alzheimer’s Disease Drug Candidate

DUBLIN–(BUSINESS WIRE)–Alkermes plc (NASDAQ: ALKS) today announced the initiation of a phase 1 clinical study of ALKS 7119, an oral, investigational drug candidate being developed for the treatment of agitation in patients with Alzheimer’s disease (AD) and other central nervous system (CNS) indications. The double-blind, placebo-controlled study will evaluate the …

Read More »